Abstract:Thymosin alpha 1 (Tα1) is a highly conserved 28 amino-acid peptide naturally occurring in the thymus and plays critical roles in T cell maturity and differentiation. Its synthetic form, thymalfasin, has been approved by various regulatory agencies in the treatment of hepatitis B viral infection and as an enhancer of vaccine response in immune-compromised populations. In China, it has also widely utilized in patients with cancer and severe infections, as well as the emergency use during (Severe Acute Respiratory Syndrome)SARS and COVID-19 pandemic as an immune-regulator. Recent studies showed that Tα1 could significantly improve overall survival (OS) in patients with surgically resectable non-small cell lung cancer (NSCLC) and liver cancers in the adjuvant setting. For patients with locally advanced, unresectable NSCLC, Tα1 could significantly reduce chemoradiation-induced lymphopenia, pneumonia, and trending improvement of OS. Preclinical evidence are emerging to demonstrate that Tα1 may augment efficacy of cancer chemotherapy by reversing efferocytosis-induced M2 polarization of macrophages via activation of a TLR7/SHIP1 axis and enhancing anti-tumor immunity by turning "cold-tumors" to "hot-tumors"; a protective role in reducing colitis caused by immune check-point inhibitors (ICIs). Potential enhancement of ICIs' clinical efficacies has also been indicated. ICIs have transformed ways treating patients with cancer but limitations such as relatively low response rates and certain safety issues remains. Given the roles of Tα1 in regulating cellular immunities and exceptional safety profiles demonstrated in decades clinical uses, we believe that it is plausible to explore implications of Tα1 the immune-oncology setting by combining with ICI-based therapeutic strategies. Background Activities of Tα1. Tα1 is a biological response modifier which activates various cells in the immune system [1-3]. Tα1 is therefore expected to have clinical benefits in disorders where immune responses are impaired or ineffective. These disorders include acute and chronic infections, cancers, and vaccine non-responsiveness. In severe sepsis, for example, sepsis-induced immunosuppression is increasingly recognized as the overriding immune dysfunction in these vulnerable patients [4] and there is now agreement that many patients with severe sepsis survive the first critical hours of the syndrome but eventually die later due to patients' immunosuppression which make the system difficulty to fight the primary bacterial infection, decreased resistance to secondary nosocomial infections, and reactivation of viral infections [5]. Tα1 has been shown to restore immune functions and help to reduce mortality in patients with severe sepsis.

Expression, Purification and Characterization of A Novel Soluble Human Thymosin Alpha1 Concatemer Exhibited A Stronger Stimulation on Mice Lymphocytes Proliferation and Higher Anti-tumor Activity

Construction, Expression, and Characterization of Thymosin Alpha 1 Tandem Repeats in Escherichia Coli

Thymosin Α-1 in Cancer Therapy: Immunoregulation and Potential Applications

Construction and application of a yeast expression system for thymosin α1

Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life

Construction and application of a yeast expression system for thymosin alpha 1

Expression,Purification and Identification of Recombinant Human Thymosin-alpha 1 in Escherichia coli

Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer

Intein-mediated Expression, Purification, and Characterization of Thymosin Α1–thymopentin Fusion Peptide in Escherichia Coli

Bioactivity and pharmacokinetics of two human serum albumin–thymosin α1-fusion proteins, rHSA-Tα1 and rHSA-L-Tα1, expressed in recombinant Pichia pastoris

The In Vitro Immunomodulatory and Anti-Tumor Activity of Thymosin alpha 1-Thymopentin Fusion Peptide

[Construction of Eukarocyte Expression Recombinant of Human Thymosin Alpha1 and Its Influnce to Immune Activity of PBLs Transfected with the Recombinant Pbk-T Alpha1]

Overexpression of Soluble Human Thymosin Alpha 1 in Escherichia Coli.

Thymosin alpha 1: biological activities, applications and genetic engineering production.

Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris.

Expression of Bioactive Thymosin Α1 Using Marker Free Transgenic Tobacco.

Immunomodulatory Function of Orally Administered Thymosin Α1

Cloning Expression and Purification of Recombinant Thymosin #Alpha#_(1)

Expression of Thymosin Α1-Thymopentin Fusion Peptide in Pichia Pastoris and Its Characterization

Thymosin alpha 1 - Reimagine its broader applications in the immuno-oncology era

A Modified Thymosin Alpha 1 Inhibits the Growth of Breast Cancer Both in Vitro and in Vivo: Suppressment of Cell Proliferation, Inducible Cell Apoptosis and Enhancement of Targeted Anticancer Effects